Can the severity of dependence scale be usefully applied to 'ecstasy'?

Neuropsychobiology

Volumn 60, Issue 3-4, 2009, Pages 137-147

  Bruno, Raimondo ^a   Matthews, Allison J ^a   Topp, Libby ^b   Degenhardt, Louisa ^c   Gomez, Rapson ^a   Dunn, Matthew ^c  

^a UNIVERSITY OF TASMANIA   (Australia)

^b Justice Health Centre for Health Research in Criminal Justice   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Drug dependency; Factor structure; Methylenedioxymethamphetamine; Screening tests; Severity of Dependence Scale

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; METHAMPHETAMINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; AUSTRALIA; CONSTRUCT VALIDITY; CONTROLLED STUDY; CRIME; CROSS-SECTIONAL STUDY; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; EDUCATIONAL STATUS; FEMALE; FINANCIAL MANAGEMENT; HEALTH CARE ACCESS; HEALTH CARE PERSONNEL; HEALTH SERVICE; HEALTH SURVEY; HIGH RISK BEHAVIOR; HUMAN; LEGAL ASPECT; MAJOR CLINICAL STUDY; MALE; PATIENT COUNSELING; PRIORITY JOURNAL; RATING SCALE; SEVERITY OF DEPENDENCE SCALE; SOCIAL PROBLEM; UNEMPLOYMENT; UNSAFE SEX; WORK;

ADOLESCENT; ADULT; AMPHETAMINE-RELATED DISORDERS; CENTRAL NERVOUS SYSTEM STIMULANTS; CROSS-SECTIONAL STUDIES; FEMALE; HALLUCINOGENS; HUMANS; MALE; METHAMPHETAMINE; MIDDLE AGED; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RISK-TAKING; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 70449493477     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000253550     Document Type: Article

References (90)

1. United Nations Office on Drugs and Crime: World Drug Report 2007. Geneva, United Nations Office on Drugs and Crime, 2008.
2. Kalechstein AD, De La Garza R, Mahoney JJ, Fantegrossi WE, Newton TF: MDMA use and neurocognition: a meta-analytic review. Psychopharmacology 2007; 189: 531-537.
3. Zakzanis KK, Campbell Z, Jovanovski D: The neuropsychology of ecstasy (MDMA) use: a quantitative review. Hum Psychopharmacol 2007; 22: 427-435.
4. Guillot C: Is recreational ecstasy (MDMA) use associated with higher levels of depressive symptoms? J Psychoactive Drugs 2007; 39: 31-39.
5. Falck RS, Wang J, Carlson RG: Depressive symptomatology in young adults with a history of MDMA use: a longitudinal analysis. J Psychopharmacol 2008; 22: 47-54.
6. Topp L, Hall W, Hando J: Is there a dependence syndrome for ecstasy? National Drug and Alcohol Research Centre Technical Report No 51. Sydney, NDARC, 1997.
7. Jansen KLR: Ecstasy (MDMA) dependence. Drug Alcohol Depend 1999; 53: 121-124.
8. Cottler LB, Womack SB, Compton WM, Ben-Abdallah A: Ecstasy abuse and dependence among adolescents and young adults: applicability and reliability of DSM-IV criteria. Hum Psychopharmacol Clin Exp 2001; 16: 599-606.
9. Von Sydow K, Lieb R, Pfister H, Hofler M, Wittchen H-U: Use, abuse and dependence of ecstasy and related drugs in adolescents and young adults - a transient phenomenon? Results from a longitudinal community study. Drug Alcohol Depend 2002; 66: 147-159.
10. Yacoubian GS, Peters RJ, Palacios WR, Link TC: Identifying the perceived and diagnosed prevalence of ecstasy dependence among club rave attendees: J Ethnicity Subst Abuse 2004; 3: 33-45.
11. Yen C, Hsu S: Symptoms of ecstasy dependence and correlation with psychopathology in Taiwanese adolescents. J Nerv Ment Dis 2007; 195: 866-869.
12. Scheier L, Abdullah A, Inciardi J, Copeland J, Cottler L: Tri-city study of Ecstasy use problems: a latent class analysis. Drug Alcohol Depend 2008; 98: 249-263.
13. Abdallah A, Scheier L, Inciardi J, Copeland J, Cottler L: A psycho-economic model of ecstasy consumption and related consequences: a multi-site study with community samples. Subst Use Misuse 2007; 42: 1651-1684.
14. Milani M: The Nature of Ecstasy Dependence. Abstract Presented at the Psychobiology of MDMA or Ecstasy International Conference, Victoria, 11-12 September 2008.
15. Shuglin AT: The background and chemistry of MDMA. J Psychoactive Drugs 1986; 18: 291-304.
16. Solowij N, Hall W, Lee N: Recreational MDMA use in Sydney: a profile of 'ecstasy' users and their experiences with the drug. Br J Addict 1992; 87: 1161-1172.
17. Winstock AR, Griffiths P, Stewart D: Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug Alcohol Depend 2001; 64: 9-17.
18. Black E, Dunn M, Degenhardt L, Campbell G, George J, Kinner S, Matthews A, Quinn B, Roxburgh A, Urbancic-Kenny A, White N: Australian Trends in Ecstasy and Related Drug Markets 2007: Findings from the Ecstasy and Related Drugs Reporting System. Australian Drug Trends Series No 10. Sydney, National Drug and Alcohol Research Centre, 2008.
19. Verheyden SL, Henry JA, Curran HV: Acute, subacute and long-term subjective consequences of 'ecstasy' (MDMA) consumption in 430 regular users. Hum Psychopharmacol Clin Exp 2003; 18: 507-517.
20. Leung K, Li J, Tsay W, Callahan C, Liu S, Hsu J, Hoffer L, Cottler L: Dinosaur girls, candy girls and Trinity: voices of Taiwanese club drug users. J Ethn Subst Abuse 2008; 7: 237-257.
21. Substance Abuse and Mental Health Services Administration: Treatment Episode Data Set (TEDS). Highlights - 2006. National Admissions to Substance Abuse Treatment Services, DASIS Series: S 40, Rockville, 2008.
22. Australian Institute of Health and Welfare: Alcohol and other drug treatment services in Australia 2005-2006: report on the National Minimum Data Set. Drug Treatment Series No 7, cat No HSE 53. Canberra, AIHW, 2007.
23. Schifano F: Potential human neurotoxicity of MDMA ('Ecstasy'): subjective self-reports, evidence from an Italian drug addiction centre and clinical case studies. Neuropsychobiology 2000; 42: 25-33.
24. Maxwell JC, Spence RT: Profiles of club drug users in treatment. Subst Use Misuse 2005; 40: 1409-1426.
25. Hopfer C, Mendelson B, Van Leeuwen JM, Kelly S, Hooks S: Club drug use among youths in treatment for substance abuse. Am J Addict 2006; 15: 94-99.
26. Trigo JE, Panayi F, Soria G, Maldonado R, Robeldo P: A reliable model of intravenous MDMA self-administration in naive mice. Psychopharmacology 2006; 184: 212-220.
27. Fantegrossi WE: Reinforcing effects of methylenedioxymethamphetamine congeners in rhesus monkeys: are intravenous self-administration experiments relevant to MDMA neurotoxicity? Psychopharmacology 2007; 189: 471-482.
28. Robeldo P, Balerio G, Berrendero F, Maldonado R: Study of the behavioural responses related to the potential addictive properties of MDMA in mice. Naunyn-Schmiedeberg's Arch Pharmacol 2004; 369: 338-349.
29. Daza-Losada M, Do Couto BR, Manzanedo C, Aguilar MA, Rodriguez-Arias M, Minarro J: Rewarding effects and reinstatement of MDMA-induced CPP in adolescent mice. Neuropsychopharmacology 2007; 32: 1750-1759.
30. Daniela E, Gittings D, Schenck S: Conditioning following repeated exposure to MDMA in rats: role in the maintenance of MDMA self-administration. Behav Neurosci 2006; 120: 1144-1150.
31. Bankson MG, Yamamoto BK: Serotonin- GABA interactions modulate MDMA-induced mesolimbic dopamine release. J Neurochem 2004; 91: 852-859.
32. Robeldo P, Mendizabai V, Ortuno J, De La Torre R, Kieffer BL, Maldonado R: The rewarding properties of MDMA are preserved in mice lacking - -opioid receptors. Eur J Neurosci 2004; 20: 853-858.
33. Koob GF: The neurobiology of addiction: a neuroadaptational view relevant for diagnosis. Addiction 2006; 101(suppl 1):23-30.
34. Lile JA, Ross JT, Nader MA: A comparison of the reinforcing efficacy of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') with cocaine in rhesus monkeys. Drug Alcohol Depend 2005; 78: 135-140.
35. Wang Z, Woolverton WL: Estimating the relative reinforcing strengths of ( 8 )-3,4-methyl enedioxymethamphetamine (MDMA) and its isomers in rhesus monkeys: comparison to (+)-methamphetamine. Psychopharmacology 2007; 189: 483-488.
36. Parrott AC: Chronic tolerance to recreational MDMA (3,4- methylenedioxymethamphetamine) or ecstasy. J Psychopharmacol 2005; 19: 71-83.
37. Gawin FH, Kleber HD: Abstinence symptomatology and psychiatric diagnosis in cocaine abusers: clinical observations. Arch Gen Psychiatry 1986; 43: 107-113.
38. Curran HV, Travill RA: Mood and cognitive effects of 8 -3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'): week-end 'high' followed by mid-week low. Addiction 1997; 92: 821-831.
39. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI: The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'). Pharmacol Rev 2003; 55: 463-508.
40. Parrott A, Lasky J: Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance. Psychopharmacology 1998; 139: 261-268.
41. Edwards G, Gross M: Alcohol dependence: provisional description of a clinical syndrome. Br Med J 1976; 6107: 1058-1061.
42. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4, rev. Arlington, American Psychiatric Association, 2000.
43. Quinn C, Breen C, White B: Illicit tablet market in Victoria. Party Drug Trends Bulletin, June 2004. Sydney, National Drug and Alcohol Research Centre, University of New South Wales, 2004.
44. Topp L, Darke S: The applicability of the dependence syndrome to amphetamine. Drug Alcohol Depend 1997; 48: 113-118.
45. Nelson CB, Rehm J, Ustun TB, Grant B, Chatterji S: Factor structures for DSM-IV substance disorder criteria endorsed by alcohol, cannabis, cocaine and opiate users: results from the WHO reliability and validity study. Addiction 1999; 94: 843-855.
46. Morgenstern J, Langenbucher J, Labouvie EW: The generalisability of the dependence syndrome across substances: an examination of some properties of the proposed DSM-IV dependence criteria. Addiction 1994; 89: 1105-1115.
47. Hasin D, Hatzenbuehler ML, Keyes K, Ogburn E: Substance use disorder: Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) and International Classification of Diseases, tenth edition (ICD-10). Addiction 2006; 101(suppl 1): 59-75.
48. Nestler EJ: Is there a common molecular pathway for addiction? Nat Neurosci 2005; 8: 1445-1449.
49. Schuckit MA, Saunders JB: The empirical basis of substance use disorders diagnosis: research recommendations for the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V). Addiction 2006; 101(suppl 1):170-173.
50. Edwards G, Arif A, Hodgston R: Nomenclature and classification of drug- and alcoholrelated problems: a shortened version of a WHO memorandum. Drug Alcohol Rev 1984; 3: 76-85.
51. Gossop M, Darke S, Griffiths P, Hando J, Powis B, Hall W, Strang J: The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction 1995; 90: 607-614.
52. Gossop M, Best D, Marsden J, Strang J: Testretest reliability of the Severity of Dependence Scale. Addiction 1997; 92: 353-354.
53. Kaye S, Darke S: Determining a diagnostic cut-off on the Severity of Dependence Scale (SDS) for cocaine dependence. Addiction 2002; 97: 727-731.
54. Topp L, Mattick RP: Choosing a cut-off on the Severity of Dependence Scale (SDS) for amphetamine users. Addiction 1997; 92: 839-845.
55. Swift W, Copeland J, Hall W: Choosing a diagnostic cut-off for cannabis dependence. Addiction 1998; 93: 1681-1692.
56. De las Cuevas C, Sanz EJ, De La Fuente JA, Padilla J, Berenguer JC: The Severity of Dependence Scale (SDS) as screening test for benzodiazepine dependence: SDS validation study. Addiction 2000; 95: 245-250.
57. Leung K, Cottler L: Ecstasy and other club drugs: a review of recent epidemiologic studies. Curr Opin Psychiatry 2008; 21: 234-241.
58. Topp L, Breen C, Kaye S, Darke S: Adapting the Illicit Drug Reporting System (IDRS) methodology to examine the feasibility of monitoring trends in party drug markets. Drug Alcohol Depend 2004; 73: 189-197.
59. Stafford J, Degenhardt L, Dunn M, Fischer J, George J, Johnston J, Matthews A, Newman J, Proudfoot P, Weekly J: Australian trends in Ecstasy and related drug markets 2005: findings from the Party Drugs Initiative (PDI). National Drug and Alcohol Research Centre Monograph No 58. Sydney, NDARC, 2006.
60. Dunn M, Degenhardt L, Campbell G, George J, Johnston J, Kinner S, Mathews A, Newman J, White N: Australian trends in Ecstasy and related drug markets 2006: findings from the Ecstasy and Related Drugs Reporting System (EDRS). National Drug and Alcohol Research Centre Monograph No 61. Sydney, NDARC, 2007.
61. Steiger JH: Structural model evaluation and modification: an interval estimation approach. Multivar Behav Res 1990; 25: 173-180.
62. Bentler PM: Comparative fit indexes in structure models. Psychol Bull 1990; 107: 238-246.
63. Marsh HW, Hau KT, Wen ZL: In search of golden rules: comment on hypothesis testing approaches to setting cutoff values for fit indexes and dangers in overgeneralizing Hu and Bentler's 1999 findings. Struct Equation Modelling 2004; 11: 320-341.
64. Yuan KH: Fit indices versus test statistics. Multivar Behav Res 2005; 40: 115-148.
65. Barrett P: Structural equation modelling: adjudging model fit. Pers Indiv Diff 2007; 42: 815-824.
66. Hu L, Bentler P: Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. Struct Equation Modelling 1999; 6: 1-55.
67. Mulaik S: There is a place for approximate fit in structural equation modelling. Pers Indiv Diff 2007; 42: 883-891.
68. Steiger JH: Understanding the limitations of global fit assessment in structural equation modelling. Pers Indiv Diff 2007; 42: 893-898.
69. Bruno R, Matthews A: Psychometric characteristics of the Severity of Dependence Scale for methamphetamine and 'ecstasy'. Paper presented at the 2006 Australasian Professional Society on Alcohol and Other Drugs Conference, Cairns, 2006.
70. Gunter TT, Arndt S, Wenman G: Characteristics of admissions for primary stimulant dependence during 2001. Subst Use Misuse 2006; 41: 1277-1286.
71. Darke S, Ross J: Polydrug dependence and psychiatric comorbidity among heroin injectors. Drug Alcohol Depend 1997; 48: 135-141.
72. Ciraulo DA, Piechniczek-Buczek J, Iscan EN: Outcome predictors in substance use disorders. Psychiatr Clin North Am 2003; 26: 381-409.
73. Topp L, Mattick RP: Validation of the amphetamine dependence syndrome and the SAmDQ. Addiction 1997; 92: 151-162. (Pubitemid 27101722)
74. De La Garza R, Fabrizio KR, Gupta A: Relevance of rodent models of intravenous MDMA self-administration to human MDMA consumption patterns. Psychopharmacology 2007; 189: 425-434.
75. Topp L, Hando J, Dillon P, Roche A, Solowij N: Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend 1999; 55: 105-115.
76. Parrott AC: MDMA (3,4-methylenedioxymethamphetamine) or ecstasy: the neuropsychobiological implications of taking it at dances and raves. Neuropsychobiology 2004; 50: 329-335.
77. Parrott AC, Rodgers J, Buchanan T, Ling J, Heffernan T, Scholey AB: Dancing hot on ecstasy: physical activity and thermal comfort ratings are associated with the memory and other psychobiological problems reported by recreational MDMA users. Hum Psychopharmacol 2006; 21: 285-298.
78. Soar K, Turner JJ, Parrott AC: Problematic vs. non-problematic ecstasy/MDMA use: the influence of drug usage patterns and pre-existing psychiatric factors. J Psychopharmacol 2006; 20: 417-424.
79. Parrott AC: MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress. J Psychopharmacol 2006; 20: 147-163.
80. Parrott AC, Milani RM, Gouzoulis-Mayfrank E, Daumann J: Cannabis and ecstasy/ MDMA (3,4-methylenedioxymethamphetamine): an analysis of their neuropsychobiological interactions in recreational users. J Neural Transm 2007; 114: 959-968.
81. Koob GF, le Moal M: Neurobiology of Addiction. London, Elsevier, 2006.
82. West R: Theory of Addiction. Oxford, Blackwell Publishing, 2006.
83. Yucel M, Lubman DI: Neurocognitive and neuroimaging evidence of behavioural dysregulation in human drug addiction: implications for diagnosis, treatment and prevention. Drug Alcohol Rev 2007; 26: 33-39.
84. Cools R, Blackwell A, Clark L, Menziea L, Cox S, Robins TW: Tryptophan depletion disrupts the motivational guidance of goaldirected behaviour as a function of trait impulsivity. Neuropsychopharmacology 2005; 30: 1362-1373.
85. Morgan MJ, Impallomeni LC, Pirona A, Rogers RD: Elevated impulsivity and impaired decision-making in abstinent ecstasy (MDMA) users compared to polydrug and drug-naive controls. Neuropsychopharmacology 2006; 31: 1562-1573.
86. Quednow BB, Kuhn K, Hoppe C, Westheide J, Maier W, Daum I, Wagner M: Elevated impulsivity and impaired decision-making cognition in heavy users of MDMA ('ecstasy'). Psychopharmacology 2007; 198: 517-530.
87. Topp L, Barker B, Degenhardt L: The external validity of results derived from ecstasy users recruited using purposive sampling strategies. Drug Alcohol Depend 2004; 73: 33-40.
88. Darke S: Self-report among injecting drug users: a review. Drug Alcohol Depend 1998; 51: 253-263.
89. Quinn C, Dunn M, Degenhardt L: The illicit tablet market in Victoria, 2004-2007. EDRS Drug Trends Bulletin, December 2007. Sydney, National Drug and Alcohol Research Centre, University of New South Wales, 2007.
90. Parrott AC: Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity. Psychopharmacology 2004; 173: 234-241.